Alpha Cognition Announces Participation in January Investor Conferences

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is scheduled to participate in the following investor conferences in January 2022:

LifeSci Advisors Partners Corporate Access Event, January 5-7
The Company will be participating in the LifeSci Advisors Partners Corporate Access Event with one-on-one meetings.

BIO Partnering at JPM, January 10-14
The Company will be participating in the BIO partnering event at the 2022 JP Morgan Healthcare Conference.

H.C. Wainwright 2022 BioConnect Conference, January 10-13
The Company will be participating in the H.C. Wainwright BioConnect Conference with a virtual presentation that will be available on demand, as well as one-on-one meetings.

The company has also posted an updated investor presentation on the Events and Presentation section of our Investor Website, available here.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS).

ALPHA-1062, is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with minimal gastrointestinal side effects and novel routes of administration. ALPHA-1062's active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia and in a nasal spray formulation to treat traumatic brain injury.

ALPHA-0602 (Progranulin) is expressed in several cell types in the central nervous system and in peripheral tissues, regulates cell survival and certain inflammatory processes, and plays a major role in regulating lysosomal function and microglial responses to disease. Its use for the treatment of neurodegenerative diseases has been patented by the Company and granted an Orphan Drug Designation.